We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Federal Off-Label Prosecution On the Rise, Experts Warn
Federal Off-Label Prosecution On the Rise, Experts Warn
August 30, 2006
As the drug industry seeks to get more value out of its R&D investment by promoting additional uses for already-approved drugs, several federal agencies are aggressively targeting the practice — a move that will hurt public health protection, stifle innovation and may violate the First Amendment, industry attorneys say.